top of page
Search

Proseek Bio Raises A$1.5M to Advance Ovarian Cancer Diagnostics

  • 10 hours ago
  • 2 min read

Proseek Bio has closed an oversubscribed A$1.5M seed round to advance the development of OC-Triage, our blood-based test for ovarian cancer.


This milestone reflects growing recognition of both the clinical need and the commercial opportunity in women’s health; a category that has historically been under-served and under-capitalised.


Addressing a Critical Diagnostic Gap

Today, up to 80% of surgeries for suspected ovarian cancer are ultimately benign.


This reflects a fundamental gap in how ovarian cancer is currently diagnosed and triaged. Clinicians often lack accurate, non-invasive tools to confidently distinguish between benign and malignant cases, leading to unnecessary surgery or delays in appropriate care.


Better diagnostics can play a critical role in improving decision-making earlier in the patient journey.


Advancing OC-Triage

The funding will support the next stage of development for OC-Triage, as we move toward clinical lab deployment and validation.


OC-Triage is designed to support earlier and more precise clinical decision-making, helping to:

  • improve referral pathways

  • reduce unnecessary surgical intervention

  • enable more timely care for high-risk patients


At Proseek Bio, our focus is on building deployable diagnostic platforms that integrate into real clinical workflows. This ensures innovation translates into practical, scalable use in healthcare settings.


While our initial focus is ovarian cancer, the broader ambition extends beyond a single indication.


A Shift in Women’s Health Investment

Women’s health has long been framed as a niche or impact-driven category. In reality, it represents one of the most significant and under-recognised opportunities in healthcare.

We are now seeing a shift: capital is beginning to catch up to the scale of both the unmet clinical need and the market opportunity.


This round brings together investors who recognise that potential and are aligned with our long-term vision.


Backed by Strong Partners

We are grateful for the support of our investors:

  • Edale Capital

  • Scale Investors

  • AngelLoop

  • AusHealth


Alongside private investment, Proseek Bio has also received non-dilutive support from:

  • CSIRO (ON Accelerate and Kick-Start)

  • Advance Queensland

  • Brisbane Economic Development Agency (Medtech Global Accelerator)


Featured in the Media

Our recent raise and the broader opportunity in ovarian cancer diagnostics have been featured in Capital Brief.



Looking Ahead

While this funding marks an important milestone, it is very much the beginning of the next phase.


The work ahead is focused on translating validated science into clinically deployable tools — and continuing to build with partners who see both the impact and the opportunity in this space.

bottom of page